Ostatné · ELV
Elevance Health, Inc.
Fundamenty firmy Healthcare · Healthcare Plans · United States
Hodnotenie 0–10, vypočítané z údajov firmy
Analytici 21 hodnotení
nákup
- Najnižší cieľ
- 393,00
- Priemerný cieľ
- 451,38
- Najvyšší cieľ
- 492,00
- Potenciál
- +15,5 %
Odhad zisku na akciu (EPS)
| Obdobie | Odhad | Rozpätie | Pred rokom | Rast |
|---|---|---|---|---|
| tento štvrťrok | 4,66 | 4,55–4,99 | 6,03 | −22,7 % |
| budúci štvrťrok | 2,43 | 1,91–3,31 | 3,33 | −27,0 % |
| tento rok | 27,17 | 27,00–28,25 | 30,29 | −10,3 % |
| budúci rok | 29,54 | 29,00–31,00 | 27,17 | +8,7 % |
Odhad tržieb
| Obdobie | Odhad | Pred rokom | Rast |
|---|---|---|---|
| tento štvrťrok | 49,1 mld. | 50,1 mld. | −1,9 % |
| budúci štvrťrok | 48,1 mld. | 49,3 mld. | −2,4 % |
| tento rok | 196,6 mld. | 197,6 mld. | −0,5 % |
| budúci rok | 200,3 mld. | 196,6 mld. | +1,9 % |
Nákupy a predaje manažérov insider
| Kto | Čo | Hodnota | Dátum |
|---|---|---|---|
| Peru Ramiro GDirector | nákup | 366 050 | 17.07. |
| Boudreaux Gail A KoziaraChief Executive Officer | nákup | 1,0 mil. | 17.07. |
| Penczek Ronald WOfficer | predaj | 148 766 | 12.06. |
| Dixon Robert L JrDirector | predaj | 60 667 | 11.06. |
| Penczek Ronald WOfficer | predaj | 617 192 | 19.05. |
| Penczek Ronald WOfficer | uplatnenie opcií | 450 579 | 19.05. |
| Jallal BahijaDirector | odmena v akciách | – | 13.05. |
| Neri Antonio FDirector | odmena v akciách | – | 13.05. |
| Devore Susan DDirector | odmena v akciách | – | 13.05. |
| Strable-Soethout Deanna DDirector | odmena v akciách | – | 13.05. |
| Schneider Ryan M.Director | odmena v akciách | – | 13.05. |
| Collis Steven HowardDirector | odmena v akciách | – | 13.05. |
Kto vlastní akcie
Slávni investori: Seth Klarman · 9.1 %
Blackrock Inc.8,76 %
Vanguard Capital Management LLC6,48 %
State Street Corporation4,81 %
Wellington Management Group, LLP4,25 %
Vanguard Portfolio Management LLC2,87 %
Sanders Capital, LLC2,69 %
Geode Capital Management, LLC2,38 %
Harris Associates L.P.2,27 %
O firme (popis z Yahoo Finance, anglicky)
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Názor AI
Krátke zhodnotenie trendu, správ a blížiacich sa udalostí.
📅 Výsledky hospodárenia: Streda 21. 10. · odhad EPS 4,66
Odporúčania
K tomuto aktívu zatiaľ nemáme odporúčanie.
Predikcie
Žiadne predikcie.
Súvisiace správy
Žiadne správy so značkou ELV.